Research Areas of AG Flörcken
Sie befinden sich hier:
Soft tissue sarcomas are rare and heterogeneous neoplasms of mesenchymal origin. Although major steps have been established toward a comprehensive molecular and immunological characterization, no reliable predictive or prognostic markers have been identified and only limited correlations have been found between clinical, molecular, and immunological analyses. We aim to integrate these data to understand relevant subgroups and to possibly identify reliable biomarkers.
Comprehensive and longitudinal biobanking in soft tissue and bone sarcoma
We are establishing a comprehensive and longitudinal biobanking for soft tissue and bone sarcomas at the Charité in cooperation with the ZeBanc Berlin. This work is supported by the German Cancer Consortium (Deutsches Konsortium für translationale Krebsforschung, DKTK). A sub-project with a special focus on adolescents and young adults (AYA) is generously funded by the Monika Kutzner Stiftung.
Clinical assessment of relevant subgroups in the Charité sarcoma cohort
We aim to characterize relevant clinical subgroups of these heterogeneous diseases to further personalize therapeutic strategies.
- Striefler JK, Brandes F, Baur A, Pfitzner BM, Kaul D, Rau D, Dörr A, Schmiester M, Koulaxouzidis G, Bullinger L, Märdian S, Flörcken A.
Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience.
BMC Cancer 2020, 20(1):68.
Molecular characterization of soft tissue sarcoma
Our approach towards a detailed molecular understanding of different genetic and histologic subtypes of the diseases in individual patients will help to individualize therapies in soft tissue and bone sarcoma.
- Schmiester M, Dolnik A, Kornak U, Hummel M, Pfitzner B, Treue D, Hartmann A, Agaimy A, Weyerer V, Lekaj A, Brakemeier S, Peters R, Öllinger R, Märdian S, Bullinger L, Striefler JK, Flörcken A.
TFE3 Activation in a TSC1-Altered PEComa: Challenging the Dichotomy of the Underlying Pathogenic Mechanisms.
J Pathol Clin Res. 2021 Jan;7(1):3-9.
Immunomodulation in metastatic renal cell carcinoma
We further focus on the understanding of tumor-induced immunosuppression in metastatic renal cell carcinoma and the immunomodulation through novel targeted therapies and immunotherapeutics.
- Flörcken A, Grau M, Wolf A, Weilemann A, Kopp J, Dörken B, Blankenstein T, Pezzutto A, Lenz P, Lenz G, Westermann J.
Gene expression profiling of peripheral blood mononuclear cells during treatment with a gene-modified allogeneic tumor cell vaccine in advanced renal cell cancer: Tumor-induced immunosuppression and a possible role for NF-kB.
International Journal of Cancer 2015,136(8):1814-26.